{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:31:52Z","timestamp":1765175512668,"version":"3.46.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Hypertrophic cardiomyopathy (HCM) is an autosomal dominant cardiovascular disease characterised by myocardial hypertrophy with a prevalence of approximately 0.2%\u20130.5%. Recently, in addition to mutations in genes encoding sarcomeric proteins, which have traditionally been implicated in the development of HCM, mutations in genes encoding non-sarcomeric proteins have also been found to be associated with the development of HCM.This report details the first documented case in China of severe HCM caused by compound heterozygous mutations in the non-sarcomeric proteins\n                      <jats:italic>Alpha-kinase 3<\/jats:italic>\n                      (\n                      <jats:italic>ALPK3<\/jats:italic>\n                      ) gene.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      This article reports the case of an 18-year-old female patient with HCM, who presented to hospital with sudden transient loss of consciousness while hiking,and the diagnosis was confirmed by echocardiography and genetic testing. Whole exome sequencing revealed a novel compound heterozygous variant in the\n                      <jats:italic>ALPK3<\/jats:italic>\n                      gene (c.4234C\u2009&amp;gt;\u2009T nonsense mutation and c.3491G\u2009&amp;gt;\u2009A missense mutation) in the proband, which was reported for the first time in China. The patient presented with severe myocardial hypertrophy, biventricular involvement, occult biventricular obstruction, simian crease, history of syncope and high risk of sudden death. After ineffective conservative pharmacological treatment, the patient underwent the first international percutaneous intramyocardial septal radiofrequency ablation (PIMSRA, Liwen procedure), which resulted in complete remission of clinical symptoms 6 months after the procedure. It strongly supports the consideration of the Liwen procedure as an effective therapeutic strategy for similar patients harboring pathogenic\n                      <jats:italic>ALPK3<\/jats:italic>\n                      variants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This case suggests that compound heterozygosity for nonsense mutations combined with missense mutations in the\n                      <jats:italic>ALPK3<\/jats:italic>\n                      gene can lead to early-onset severe HCM, enriches the mutation spectrum of the\n                      <jats:italic>ALPK3<\/jats:italic>\n                      gene, reveals high frequency mutation sites in exons 4 and 10 specific to East Asian populations, suggesting potential racial genetic heterogeneity, and that the Liwen procedure is a safe and effective treatment for HCM.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1671882","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:34Z","timestamp":1765175374000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel compound heterozygous ALPK3 mutations (c.4234C&gt;T and c.3491G&gt;A), causing hypertrophic cardiomyopathy treated with the liwen procedure: case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Wen-Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Hui","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ping","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-Feng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1161\/CIR.0000000000000938","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.16563\/j.cnki.1671-6272.2023.02.001","article-title":"The 2023 guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy in adults in China","volume":"23","year":"2023","journal-title":"Chin J Mol Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41569-021-00608-2","article-title":"Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies","volume":"19","author":"Walsh","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jacc.2015.10.093","article-title":"Biallelic truncating mutations in ALPK3 cause severe pediatric cardiomyopathy","volume":"67","author":"Almomani","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"755376","DOI":"10.3389\/fcvm.2022.755376","article-title":"Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation","volume":"9","author":"Meng","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1093\/eurheartj\/ehab424","article-title":"Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy","volume":"42","author":"Lopes","year":"2021","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/s10038-018-0492-1","article-title":"Novel ALPK3 mutation in a Tunisian patient with pediatric cardiomyopathy and facio-thoraco-skeletal features","volume":"63","author":"Jaouadi","year":"2018","journal-title":"J Hum Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3390\/genes11101201","article-title":"Two new cases of hypertrophic cardiomyopathy and skeletal muscle features associated with ALPK3 homozygous and compound heterozygous variants","volume":"11","author":"Jorholt","year":"2020","journal-title":"Genes (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"915649","DOI":"10.3389\/fmed.2022.915649","article-title":"The involvement of ALPK3 in hypertrophic cardiomyopathy in east Asia","volume":"9","author":"Dai","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e2112","DOI":"10.4244\/EIJ-D-17-00657","article-title":"Percutaneous intramyocardial septal radiofrequency ablation of hypertrophic obstructive cardiomyopathy: a novel minimally invasive treatment for reduction of outflow tract obstruction","volume":"13","author":"Liu","year":"2018","journal-title":"EuroIntervention"},{"key":"B13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamacardio.2022.0259","article-title":"Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy","volume":"7","author":"Zhou","year":"2022","journal-title":"JAMA Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijcard.2021.02.069","article-title":"Diagnostic yield of targeted next generation sequencing in 2002 Dutch cardiomyopathy patients","volume":"332","author":"Alimohamed","year":"2021","journal-title":"Int J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1161\/CIRCULATIONAHA.122.059688","article-title":"Pathogenesis of cardiomyopathy caused by variants in ALPK3, an essential pseudokinase in the cardiomyocyte nucleus and sarcomere","volume":"146","author":"Agarwal","year":"2022","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"35978","DOI":"10.1074\/jbc.M100485200","article-title":"A novel myocyte-specific gene midori promotes the differentiation of P19CL6 cells into cardiomyocytes","volume":"276","author":"Hosoda","year":"2001","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1093\/eurheartj\/ehw160","article-title":"ALPK3-deficient Cardiomyocytes generated from patient-derived induced pluripotent stem cells and mutant human embryonic stem cells display abnormal calcium handling and establish that ALPK3 deficiency underlies familial cardiomyopathy","volume":"37","author":"Phelan","year":"2016","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/cge.14656","article-title":"Unique genetic profiles in hypertrophic cardiomyopathy patients from S\u00e3o Miguel Island (Azores, Portugal)","volume":"107","author":"Duarte","year":"2025","journal-title":"Clin Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14740\/cr1449","article-title":"Overlapping phenotype of adult-onset ALPK3-cardiomyopathy in the setting of two novel variants","volume":"13","author":"Chumakova","year":"2022","journal-title":"Cardiol Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3760\/cma.j.cn112140-20210222-00150","article-title":"ALPK3 gene-related pediatric cardiomyopathy with craniofacial-skeletal features: a report and literature review","volume":"59","author":"Ding","year":"2021","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.3390\/ijms25147556","article-title":"A rare coincidence of three inherited diseases in a family with cardiomyopathy and multiple extracardiac abnormalities","volume":"25","author":"Bukaeva","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e039464","DOI":"10.1161\/JAHA.124.039464","article-title":"\u0391protein kinase 3 is essential for neonatal and adult cardiac function","volume":"14","author":"Feng","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/0300985811402841","article-title":"Cardiomyopathy in \u03b1-kinase 3 (ALPK3)-deficient mice","volume":"49","author":"Van Sligtenhorst","year":"2012","journal-title":"Vet Pathol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e034080","DOI":"10.1161\/JAHA.123.034080","article-title":"Midterm outcomes of percutaneous intramyocardial septal radiofrequency ablation for hypertrophic cardiomyopathy: a single-center, observational study","volume":"13","author":"Xie","year":"2024","journal-title":"J Am Heart Assoc"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1671882\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:36Z","timestamp":1765175376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1671882\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":24,"alternative-id":["10.3389\/fcvm.2025.1671882"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1671882","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1671882"}}